N-acetyltransferase: the practical consequences of polymorphic activity in man

References

• Agundez JAG, Garcia-Martin E. (2018). Human arylamine N-acetyltransferase type 2: phenotypic correlation with genotype – a clinical perspective. In Sim E, Laurieri N, eds. Arylamine N-acetyltransferases in health and disease: from pharmacogenetics to drug discovery and diagnostics . Singapore: World Scientific Publishing Co.; 69–89.
   Google Scholar
• Andersson BS, Beran M, Bakic M, et al. (1987). In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia. Cancer Res 47:1040–44.
   PubMed Web of Science ®Google Scholar
• Askelöf EEA, Svartz N, Willstaedt CH. (1946). Heterocyclic sulfonamido azo compounds. US Patent 2,396,145. 5 March 1946. (application date 24th January 1942). Assignee: Aktiebolaget Pharmacia, Stockholm, Sweden. 3pp.
   Google Scholar
• Atkinson AJ Jr, Lertora JJ, Kushner W, et al. (1983). Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias. Clin Pharmacol Ther 33(5):565–76.
   PubMed Web of Science ®Google Scholar
• Azad Khan, AK, Nurazzaman, M, Truelove, SC, (1983). The effect of the acetylator phenotype on the metabolism of sulphasalazine in man. J Med Genet 20:30–6.
   PubMed Web of Science ®Google Scholar
• Baer, AN, Woosley, RL, Pincus, T. (1986). Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosus. Arthritis Rheum 29:508–14.
   PubMed Web of Science ®Google Scholar
• Bajpai M, Roskos LK, Shen DD, Levy RH. (1996). Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite . Drug Metab Dispos 24:1401–03.
   PubMed Web of Science ®Google Scholar
• Baker GB, Urichuk LJ, McKenna KF, Kennedy SH. (1999). Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol 19(3):411–26.
   PubMed Web of Science ®Google Scholar
• Bandelin FJ, Malesh W. (1959). The solubility of various sulphonamides employed in urinary tract infections. J Pharmaceut Sci 48(3):177–81.
   Google Scholar
• Barrett JH, Smith G, Waxman R, et al. (2003) Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carcinogenesis 24;275–82.
   PubMed Web of Science ®Google Scholar
• Batchelor JR, Welsh KL, Mansilla-Tinoco R, et al. (1980). Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1:1107–09.
   PubMed Web of Science ®Google Scholar
• Baumann E, Preusse C. (1879). Ueber Bromophenylmercaptursäure. Ber Deut Chem Ges 12(1):806–10.
   Google Scholar
• Bax DE, Greaves MS, Amos RS. (1986). Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment. Br J Rheumatol 25:282–84.
   PubMedGoogle Scholar
• Biehl JP. (1957). Emergence of drug resistance as related to the dosage and metabolism of isoniazid. Trans Conf Chemother Tuberc. 108–113; 1957 February. US Veterans Administration Army Navy, Washington DC.
   Google Scholar
• Bluhm RE, Adedoyin A, McCarver DG, Branch RA. (1999). Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors. Clin Pharmacol Ther 65:598–605.
   PubMed Web of Science ®Google Scholar
• Bodansky HJ, Drury PL, Cudworth AG, Evans DA. (1981). Acetylator phenotypes and type I (insulin-dependent) diabetics with microvascular disease. Diabetes 30(11):907–10.
   PubMed Web of Science ®Google Scholar
• Bönicke R, Lisboa BP. (1957). Über die Erbbedingtheit der intraindividuellen Konstanz der Isoniazidausscheidung beim Menschen (Untersuchungen an eineiigen und zweieiigen Zwillingen). Naturwissenschaften 44:314.
   Web of Science ®Google Scholar
• Bonicke R, Reif W. (1953). Enzymatische Inaktivierung von Isonicotinsäurehydrazid im Menschlichen und tierischen Organismus. Archiv fur experimentelle Pathologie und Pharmackologie (Naunyn-Schmeideberg) 220;321–33.
   PubMedGoogle Scholar
• Boukouvala S, Fakis G. (2005). Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab Rev 37;511–64.
   PubMed Web of Science ®Google Scholar
• Bourdi M, Tinel M, Beaune PH, Pessayre D. (1994). Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol Pharmacol. 45(6):1287–95.
   PubMed Web of Science ®Google Scholar
• Brownson R. Chang JC. (1987). Exposure to alcohol and tobacco and the risk of laryngeal cancer. Arch Environ Health 42:192–6.
   PubMedGoogle Scholar
• Budhathoki S, Iwasaki M, Yamaji T, et al. (2019). Doneness preferences, meat and meat-derived heterocyclic amines intake, and N-acetyltransferase 2 polymorphisms: association with colorectal adenoma in Japanese Brazilians. Eur J Cancer Prev 1. DOI: 10.1097/CEJ.0000000000000506
   PubMed Web of Science ®Google Scholar
• Bulovskaya LN, Krupkin RG, Bochina TA, et al. (1978). Acetylator phenotype in patients with breast cancer. Oncology 35:185–8.
   PubMed Web of Science ®Google Scholar
• Burgess EJ, Trafford JAP. (1985). Acetylator phenotype in patients with lung cancer – a negative report. Eur J Respir Dis 67:17–9.
   PubMedGoogle Scholar
• Cartwright RA, Glasham RW, Rogers HJ, et al. (1982). Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacological epidemiological approach to bladder cancer. Lancet 2:842–6.
   PubMed Web of Science ®Google Scholar
• Cartwright RA, Adib R, Appleyard I, et al. (1983). Cigarette smoking and bladder cancer: an epidemiological enquiry in West Yorkshire. J Epidemiol Commun Health 37:256–63.
   PubMed Web of Science ®Google Scholar
• Cartwright RA. (1984). Epidemiological studies on N-acetylation and C-center ring oxidation in neoplasia. In Omenn GS, Gelboin HV, eds. Genetic variability in response to chemical exposure. . Cold Spring Harbor Laboratory. Banbury Report 16. New York, USA: CSHL Press, 359–65.
   Google Scholar
• Chan AT, Tranah GJ, Giovannucci EL, et al. (2005). Prospective study of N-acetyltransferase-2 genotypes, meat intake, smoking and risk of colorectal cancer. Int J Cancer 115;648–52.
   PubMed Web of Science ®Google Scholar
• Chekharina YA, Buloskaya LN, Pavlova MV, Krupin RG. (1978). Activity of N-acetyltransferase in pateints with malignant lymphomas. Neoplasma 25:471–5.
   PubMed Web of Science ®Google Scholar
• Chung KT. (2015). Occurrence, uses, and carcinogenicity of arylamines. Front Biosci (Elite Ed) 7(7):322–45.
   PubMedGoogle Scholar
• Cohn R. (1893). Ueber das Auftreten acetylirter Verbindungen nach Darreichung von Aldehyden. Habilitationsschrift. Zeitschrift für Physiologische Chemie 17:274–310.
   Google Scholar
• Coleman MD, Breckenridge AM, Park BK. (1989). Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br J Clin Pharmacol 28:389–95.
   PubMed Web of Science ®Google Scholar
• Coombes RC, Foster AB, Harland SJ, et al. (1982). Polymorphically acetylated aminoglutethimide in humans. Br J Cancer 46(3):340–5.
   PubMed Web of Science ®Google Scholar
• Cribb AE, Miller M, Leeder JS, et al. (1991). Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Dispos 19(5):900–6.
   PubMed Web of Science ®Google Scholar
• Crook PR, Hortas C, Roberts JM, et al. (1983). Acetylator phenotype and the effect of dapsone in rheumatoid arthritis. J Rheumatol 10:805–8.
   PubMed Web of Science ®Google Scholar
• Cui D, Wang Z, Zhao E, et al. (2011). NAT2 polymorphism and lung cancer risk: a meta-analysis. Lung Cancer 73:153–7.
   PubMed Web of Science ®Google Scholar
• Cunningham ML, Matthews HB. (1990). Evidence for an acetoxyarylamine as the ultimate mutagenic reactive intermediate of the carcinogenic aromatic amine 2,4-diaminotoluene. Mutat Res/Genet Toxicol 242(2):101–10.
   PubMed Web of Science ®Google Scholar
• Das KM, Eastwood MA. (1975). Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn’s disease. Clin Pharmacol Ther 18:514–20.
   PubMed Web of Science ®Google Scholar
• Davis CD, Schut HA, Adamson RH, et al. (1993). Mutagenic activation of IQ, PhIP and MeIQx by hepatic microsomes from rat, monkey and man: low mutagenic activation of MeIQx in cynomolgus monkeys in vitro reflects low DNA adduct levels in vivo. Carcinogenesis 14(1):61–5.
   PubMed Web of Science ®Google Scholar
• Devadatta S, Gangadharam PRJ, Andrews RH, et al. (1960). Peripheral neuritis due to isoniazid. Bull World Health Organ 23:587–98.
   PubMedGoogle Scholar
• DMBG. (2018). The database of arylamine N-acetyltransferases (NATs). Greece: Democritus University of Thrace. http://nat.mbg.duth.gr/background_2013.html - http://nat.mbg.duth.gr/Human%20NAT1%20alleles_2013.htm - http://nat.mbg.duth.gr/Human%20NAT2%20alleles_2013.htm (last accessed 14 Mar 2018).
   Google Scholar
• Doaei S, Hajiesmaeil M, Aminifard A, et al. (2018). Effects of gene polymorphisms of metabolic enzymes on the association between red and processed meat consumption and the development of colon cancer; a literature review. J Nutr Sci 7:e26.
   PubMed Web of Science ®Google Scholar
• Drozdz M, Gierek T, Jendryczko A, et al. (1987). N-acetyltransferase of patients with cancer of the larynx. Neoplasma 14(4):481–4.
   Google Scholar
• Druey J, Ringier BH. (1951). Hydrazinderivate der Phtalazin-und Pyridazinreihe. Helv Chim Acta 34(1):195–219.
   Web of Science ®Google Scholar
• Dupret JM, Grant DM. (1992). Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2. J Biol Chem 267:7381–5.
   PubMed Web of Science ®Google Scholar
• Dursun R, Dursun HG, Zamani AG, et al. (2018). NAT2 Gene polymorphisms in Turkish patients with psoriasis vulgaris. Biomed Res Int 2018:1.
   Web of Science ®Google Scholar
• Ehrenfield M, Zylber-Katz E, Levy M. (1983). Acetylation phenotype in rehumatoid arthritis. Isr J Med Sci 19:368–70.
   PubMedGoogle Scholar
• Ehrlich GE, Freeman-Narrod M, Winebrugh GS. (1979). Predominance of slow acetylators amongst patients with rheumatoid arthritis. Eur J Rheumatol Inflamm 2:196–8.
   Web of Science ®Google Scholar
• Ellard GA, Gammon PT. (1976). Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 4:83–113.
   PubMedGoogle Scholar
• Ellard GA. (1976). Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 19:610–25.
   PubMed Web of Science ®Google Scholar
• Ellinger A, Hensel M. (1914). Quantitative Studien über Acetylierungprozesse im Tierkörper. I. Mitteilung Die Bildung von p-Acetylaminobenzoesäure aus p-Aminobenzaldehyd und p-Aminobenzoesäure. Z Physiol Chem 91(1):21–44.
   Google Scholar
• Evans DAP, Manley KA, McKusick VA. (1960). Genetic control of isoniazid metabolism in man. Br Med J 2:485–91.
   PubMed Web of Science ®Google Scholar
• Evans DA, Bullen MF, Houston J, et al. (1972). Survey of human acetylator polymorphism in spontaneous disorders. J Med Genet 9:53–6.
   PubMed Web of Science ®Google Scholar
• Felder TB, McLean MA, Vestal ML, et al. (1987). Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans. Drug Metab Dispos 15(6):773–8.
   PubMed Web of Science ®Google Scholar
• Felton JS, Malfatti MA, Knize MG, et al. (1997). Health risks of heterocyclic amines. Mutat Res 376(1–2):37–41.
   PubMed Web of Science ®Google Scholar
• Fischbach T, Hertie H, Kiese M, et al. (1982). Toxicity of certain polycyclic and monocyclic N-arylacetohydroxamic acids in rats. In Kehl H, ed. Chemistry and biology of hydroxamic acids. 1ST International Symposium, Dayton, Ohio, May 1981. Basel: Karger. pp.140–8.
   Google Scholar
• Flammang TJ, Yamazoe Y, Guengerich FB, Kadlubar FF. (1987). The S-acetyl coenzyme A-dependent metabolic activation of the carcinogen N-hydroxy-2-aminofluorene by human liver cytosol and the relationship to the aromatic amine N-acetyltransferase phenotype. Carcinogenesis 8:1976–70.
   Web of Science ®Google Scholar
• Foad B, Litwin A, Zimmer H, Hess EV. (1977). Acetylator phenotype in systemic lupus erythematosus. Arthritis Rheum 20:815–8.
   PubMed Web of Science ®Google Scholar
• Frandsen H, Alexander J. (2000). N-acetyltransferase-dependent activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine: formation of 2-amino-1-methyl-6-(5-hydroxy)phenylimidazo [4,5-b]pyridine, a possible biomarker for the reactive dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Carcinogenesis 21(6):1197–203.
   PubMed Web of Science ®Google Scholar
• Fromm E, Wittmann J. (1908). Derivate des p-nitrophenols. Ber Deutsch Chem Ges 41:2264–73.
   Google Scholar
• García-Martín E, Esguevillas G, Blanca-López N, et al. (2015). Genetic determinants of metamizole metabolism modify the risk of developing anaphylaxis. Pharmacogenet Genomics 25(9):462–4.
   PubMed Web of Science ®Google Scholar
• Gawrońska-Szklarz B, Luszawska-Kutrzeba T, Czaja-Bulsa G, Kurzawski G. (1999). Relationship between acetylation polymorphism and risk of atopic diseases. Clin Pharmacol Ther 65:562–9.
   PubMed Web of Science ®Google Scholar
• Gellerman G. (2016). Recent developments in the synthesis and applications of anticancer amonafide derivatives. A mini review. Lett Drug Design Discov 13(1):47–63.
   Web of Science ®Google Scholar
• Gelmo P. (1908). Über Sulfamide der p-Amidobenzolsulfonsäure. Journal für Practische Chemie 77:369–82.
   Google Scholar
• Gibson TP, Matusik J, Matusik E, et al. (1975). Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype. Clin Pharmacol Ther 17:395–9.
   PubMed Web of Science ®Google Scholar
• Gill HJ, Tingle MD, Park BK. (1995). N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 40:531–8.
   PubMed Web of Science ®Google Scholar
• Glowinski IB, Radtke HE, Weber WW. (1978). Genetic variation in N-acetylation of carcinogenic arylamines by human and rat liver. Mol Pharmacol 14:940–9.
   PubMed Web of Science ®Google Scholar
• Gong C, Hu X, Gao Y, et al. (2011). A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review. Med Oncol 28:365–76.
   PubMed Web of Science ®Google Scholar
• Gorrod JW, Manson D. (1986). The metabolism of aromatic amines. Xenobiotica 16:933–5.
   PubMed Web of Science ®Google Scholar
• Goss PE, Jarman M, Griggs LJ. (1985). Metabolism of aminoglutethimide in humans: quantification and clinical relevance of induced metabolism. Br J Cancer 51:259–62.
   PubMed Web of Science ®Google Scholar
• Grabiec AM, Reedquist KA. (2013). The ascent of acetylation in the epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 9:311–8.
   PubMed Web of Science ®Google Scholar
• Grant DM, Blum M, Beer M, Meyer UA. (1991). Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39:184–91.
   PubMed Web of Science ®Google Scholar
• Grant DM, Lottspeich F, Meyer UA. (1989). Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver. FEBS Lett 244:203–7.
   PubMed Web of Science ®Google Scholar
• Gunnarsson I, Kanerud L, Pettersson E, et al. (1997). Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 36:1089–94.
   PubMedGoogle Scholar
• Harris HW, Knight RA, Selin MJ. (1958). Comparison of isoniazid concentrations in the blood of people of Japanese and European descent; therapeutic and genetic implications. Am Rev Tuberc 78:944–8.
   PubMedGoogle Scholar
• Hartmann M, Druey J. (1949). Hydrazine derivatives of pyridazine compounds. US Patent 2,484,029. 1st October 1949. (application date 21 Dec 1945). Assignee: Ciba Pharmaceutical Products Inc. New Jersey, USA. 4pp.
   Google Scholar
• Hein DW, Doll MA, Fretland AJ, et al. (2000). Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomark Prev 9(1):29–42.
   PubMed Web of Science ®Google Scholar
• Hein DW, Doll MA, Rustan TD, et al. (1993). Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT 1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14:1633–8.
   PubMed Web of Science ®Google Scholar
• Hein DW. (2009). N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol 5;353–66.
   PubMed Web of Science ®Google Scholar
• Hein DW. (2018). Arylamine N-acetyltransferase type 2 polymorphism and human urinary bladder and breast cancer risk. In Sim E, Laurieri N, eds. Arylamine N-acetyltransferases in health and disease: from pharmacogenetics to drug discovery and diagnostics. Singapore: World Scientific Publishing Co., 327–49.
   Google Scholar
• Hollman A. (1992). Procaine and procainamide. Br Heart J 67(2):143.
   PubMedGoogle Scholar
• Huang Y-S, Chern H-D, Su W-J, et al. (2002). Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35:883–9.
   PubMed Web of Science ®Google Scholar
• Hughes HB, Schmidt LH, Biehl JP. (1955). The metabolism of isoniazid, its implications in therapeutic use. Trans Conf Chemother Tuberc. 217–22; 1955 Feb 7-10, Atlanta, USA. US Veterans Administration Army Navy, Washington DC.
   Google Scholar
• Hughes HB. (1953). On the metabolic fate of isoniazid. J Pharmacol Exp Ther 109;444–52.
   PubMed Web of Science ®Google Scholar
• Hunyor SN. (1975). Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype. Aust N Z J Med 5:530–6.
   PubMedGoogle Scholar
• Ilett KE, Detchon P, Ingram DM, et al. (1990). Acetylation phenotype is not associated with breast cancer. Cancer Res 50(20):6649–51.
   Web of Science ®Google Scholar
• Ilett KF, David BM, Detchon P, et al. (1987). Acetylation phenotype in colorectal carcinoma. Cancer Res 47:1466–9.
   PubMed Web of Science ®Google Scholar
• Israili ZH, Cucinell SA, Vaught J, et al. (1973). Studies of the metabolism of dapsone in man and experimental animals: formation of N-hydroxy metabolites. J Pharmacol Exp Ther 187:138–50.
   PubMed Web of Science ®Google Scholar
• Jaffé M, Cohn R. (1887). Ueber das Verhalten des Furfurols im thierischen Organismus. I. Ber Dtsch Chem Ges 20(2):2311–7.
   Google Scholar
• Jaffé M. (1879). Ueber die nach Einführung von Brombenzol und Chlorbenzol im Organismus entstehenden schwefelhaltigen Säuren. Ber Deut Chem Ges 12(1):1092–8.
   Google Scholar
• Jenne JW. (1965). Partial purification and properties of the isoniazid transcatylase of human liver and relationship to the acetylation of p-aminosalicyclic acid. J Clin Invest 44:1992–2002.
   PubMed Web of Science ®Google Scholar
• Johnson N, Bell P, Jonovska V, et al. (2004). NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant. BMC Med Genet, 5:6.
   PubMedGoogle Scholar
• Johnstone EC, Marsh W. (1973). Acetylator status and response to phenelzine in depressed patients. Lancet 1:567–70.
   PubMed Web of Science ®Google Scholar
• Kalow W. (1962). Pharmacogenetics. Heredity and the response to drugs. Philadelphia: WB Saunders Co.
   Google Scholar
• Karim AK, Evans DA. (1976). Polymorphic acetylation of nitrazepam. J Med Genet 13:17–9.
   PubMed Web of Science ®Google Scholar
• Karlsson E, Molin L. (1975). Polymorphic acetylation of procaine amide in healthy subjects. Acta Medica Scandinavica 197:299–302.
   PubMedGoogle Scholar
• Kaufmann GR, Wenk M, Taeschner W, et al. (1996). N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 60:62–7.
   PubMed Web of Science ®Google Scholar
• Kelly C, Griffiths ID. (1981). Dapsone in rheumatoid arthritis. Ann Rheum Dis 40:630–2.
   PubMed Web of Science ®Google Scholar
• King CM, Glowinski IB. (1983). Acetylation, deacetylation and acyltransfer. Environ Health Perspect 49:43–50.
   PubMed Web of Science ®Google Scholar
• Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. (2005). Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 49:1733–8.
   PubMed Web of Science ®Google Scholar
• Kitas GD, Farr M, Waterhouse L, Bacon PA. (1992). Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand J Rheumatol 21:220–5.
   PubMed Web of Science ®Google Scholar
• Knight RA, Selin MJ, Harris HW. (1959). Genetic factors influencing isoniazid blood levels in humans. Trans Conf Chemother Tuberc. 52–8; 1959 Feb 2-5, St. Louis, Missouri, USA. US Veterans Administration Army Navy, Washington DC.
   Google Scholar
• Knoop F. Kertess E. (1911). Das Verhalten von α-Aminosäuren und α-Ketonsäuren im Tierkörper. Z Physiol Chem 71(3):252–65.
   Google Scholar
• Konishi K, Fukami T, Gotoh S, Nakajima M. (2017). Identification of enzymes responsible for nitrazepam metabolism and toxicity in human. Biochem Pharmacol 140:150–60.
   PubMed Web of Science ®Google Scholar
• Koroltchouk V, Stanely K, Stjernsward J, Mott K. (1987). Bladder cancer: approaches and prevention control. Bull World Health Org 65:513–20.
   PubMed Web of Science ®Google Scholar
• Kumagai S, Komada F, Kita T, et al. (2004). N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharm Res 21:324–9.
   PubMed Web of Science ®Google Scholar
• Ladero JM, Cano F. (1983). Fenotipo acetilador en la enfermedad de Basedow. Neuvos Archivos de la Facultad de Medicina 41:79–81.
   Google Scholar
• Ladero JM, Fernandez MJ, Palmeiro R, et al. (1987). Hepatic acetylator polymorphism in breast cancer patients. Oncology 44:341–4.
   PubMed Web of Science ®Google Scholar
• Ladero JM, Gonzalez JF, Benitez J, et al. (1991). Acetylator polymorphism in human colorectal carcinoma. Cancer Res 51:2098–100.
   PubMed Web of Science ®Google Scholar
• Land SJ, King CM. (1994). Characterization of rat hepatic acetyltransferase. Environ Health Perspect 102(Suppl.6):91–3.
   PubMed Web of Science ®Google Scholar
• Lang NP, Chu DZJ, Hunter CF, et al. (1986). Role of aromatic amine acetyltransferase in human colorectal cancer. Arch Surg 121:1259–61.
   PubMed Web of Science ®Google Scholar
• Laurieri N, Egleton JE, Russell AJ. (2018). Human arylamine N-acetyltransferase type 1 and breast cancer. In Sim E, Laurieri N, eds. Arylamine N-acetyltransferases in health and disease: from pharmacogenetics to drug discovery and diagnostics. Singapore: World Scientific Publishing Co., 351–84.
   Google Scholar
• Lauterburg BH, Smith CV, Todd EL, Mitchell JR. (1985). Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther 235:566–70.
   PubMed Web of Science ®Google Scholar
• Lawson DH, Henry DA, Lowe J, et al. (1979). Acetylator phenotype in spontaneous SLE and rheumatoid arthritis. Ann Rheum Dis 38:171–3.
   PubMed Web of Science ®Google Scholar
• Lawson DH, Jick H. (1977). Adverse reactions to procainamide. Br J Clin Pharmacol 4(5):507–11.
   PubMed Web of Science ®Google Scholar
• Leden L, Hanson A, Melander A, et al. (1981). Varying distribution of acetylation phenotypes in RA patients with and without Sjorgen’s syndrome. Scand J Rheumatol 10:253–5.
   PubMed Web of Science ®Google Scholar
• Legha SS, Ring S, Raber M, et al. (1987). Phase I clinical investigation of benzisoquinolinedione. Cancer Treat Rep 71(12);1165–9.
   PubMedGoogle Scholar
• Lehmann DF. (2012). The metabolic rationale for a lack of cross-reactivity between sulfonamide antimicrobials and other sulfonamide-containing drugs. Drug Metab Lett 6:129–33.
   PubMedGoogle Scholar
• LeLouet H, Ruivart M, Bierling P, et al. (1999). Lack of relevance of the acetylator status on dapsone response in chronic autoimmune thrombocytopenic purpura. Am J Hematol 62:251–2.
   PubMed Web of Science ®Google Scholar
• Levy GN, Weber WW. (2002). Arylamine acetyltransferases. In Ioannides C, ed. Enzyme systems that metabolise drugs and other xenobiotics. Chichester: Wiley & Sons, 441–57.
   Google Scholar
• Lipman F. (1945). Acetylation of sulphanilamide by liver homogenates and extracts. J Biol Chem 160:173–90.
   Web of Science ®Google Scholar
• Liu J, Ding D, Wang X, et al. (2012). N-acetyltransferase polymorphism and risk of colorectal adenoma and cancer: a pooled analysis of variations from 59 studies. PLoS One 7(8):e42797. https://doi.org/10.1371/journal.pone.0042797
   PubMed Web of Science ®Google Scholar
• Liu Y, Levy GN. (1998). Activation of heterocyclic amines by combinations of prostaglandin H synthase-1 and -2 with N-acetyltransferase 1 and 2. Cancer Lett 133:115–23.
   PubMed Web of Science ®Google Scholar
• Lower GM, Nilsson T, Bryan GT. (1976). N-Acetyltransferase phenotype of patients with “spontaneous” urinary bladder cancer. Proc Am Assoc Cancer Res 17:203.
   Google Scholar
• Marshall EF, Mountjoy CQ, Campbell IC, et al. (1978). The influence of acetylator phenotype on the outcome of treatment with phenelzine, in a clinical trial. Br J Clin Pharmacol 6:247–54.
   PubMed Web of Science ®Google Scholar
• Marshall EK, Cutting WC, Emerson K. (1938). The toxicity of sulphanilamide. J Am Med Assoc 110(4):252–7.
   Google Scholar
• Marshall EK. (1954). Acetylation of sulfonamides in the dog. J Biol Chem 211:499–503.
   PubMed Web of Science ®Google Scholar
• May DG, Porter JA, Uetrecht JP, et al. (1990). The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther 48:619–27.
   PubMed Web of Science ®Google Scholar
• Meyer H, Mally J. (1912). Über Hydrazinderivate der Pyridincarbonsäuren. Monatshefte fuer Chemie. 33(4):393–414.
   Google Scholar
• Miller ME, Garland WA, Min BH, et al. (1981). Clonazepam acetylation in fast and slow acetylators. Clin Pharmacol Ther 30(3):343–7.
   PubMed Web of Science ®Google Scholar
• Mitchell JR, Thorgeirsson UP, Black M, et al. (1975). Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 18(1):70–9.
   PubMed Web of Science ®Google Scholar
• Mitchell RS, Bell JC. (1957). Clinical implications of isoniazid PAS and streptomycin blood levels in pulmonary tuberculosis. Trans Am Clin Climatol Assoc 69:98–105.
   PubMedGoogle Scholar
• Mizuno K, Katoh M, Okumura H, et al. (2009). Metabolic activation of benzodiazepines by CYP3A4. Drug Metab Dispos 37:345–351.
   PubMed Web of Science ®Google Scholar
• Mongey AB, Sim E, Risch A, Hess E. (1999). Acetylation status is associated with serological changes but not clinically significant disease in patients receiving procainamide. J Rheumatol 26:1721–6.
   PubMed Web of Science ®Google Scholar
• Muakkassah SF, Yang WCT. (1981). Mechanism of the inhibitory action of phenelzine on microsomal drug metabolism. J Pharmacol Exp Ther 219(1):147–55.
   PubMed Web of Science ®Google Scholar
• Murali M, Manjara T, Madhuri B, et al. (2012). Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity. CNS Neurosci Ther 18(4):350–8.
   PubMed Web of Science ®Google Scholar
• Nacak M, Aynacioglu AS, Filiz A, et al. (2002). Association between the N-acetylation genetic polymorphism and bronchial asthma. Br J Clin Pharmacol 54(6):671–4.
   PubMed Web of Science ®Google Scholar
• Neubauer O, Warburg O. (1910). Über eine Synthese mit Essigsäure in der kunstlich durchbluteten Leber. (Beiträge zur Kenntnis der Leberfunktionen. II. Mitteilung). Z Physiol Chem 70(1):1–9.
   Google Scholar
• Nikolova I, Tencheva J, Voinikov J, et al. (2012). Metamizole: a review orofile of a well-known “forgotten” drug. Part I: pharmaceutical and nonclinical profile. Biotechnol Biotechnological Equipment 26(6):3329–37.
   Web of Science ®Google Scholar
• O’Neil WM, MacArthur RD, Farrough MJ, et al. (2002). Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J Clin Pharmacol 42:613–619.
   PubMed Web of Science ®Google Scholar
• Ohno M, Yamaguchi I, Yamamoto I, et al. (2000). Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4:256–61.
   PubMed Web of Science ®Google Scholar
• Ohsako S, Deguchi T. (1990). Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 265:4630–4.
   PubMed Web of Science ®Google Scholar
• Oka M, Seppala O. (1978). Acetylation phenotype in rheumatoid arthritis. Scand J Rheumatol 7:29–30.
   PubMed Web of Science ®Google Scholar
• Olivera M, Martínez C, Gervasini G, et al. (2007). Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett 1(1):3–5.
   PubMedGoogle Scholar
• OMIM. (2018). Online Mendelian inheritance in man. OMIN entries 108345 and 612182. Baltimore: John Hopkins University. https://www.ncbi.nlm.nih.gov/clinvar?term=108345[MIM] and https://www.ncbi.nlm.nih.gov/clinvar?term=612182[MIM] (last accessed 14 Mar 2018).
   Google Scholar
• Ortiz de Montellano PR, Augusto O, Viola F, Kunze KL. (1983). Carbon radicals in the metabolism of alkyl hydrazines. J Biol Chem 258(14):8623–9.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Watanabe MD. (1987). Free radical pathways in the in vitro hepatic metabolism of phenelzine. Mol Pharmacol 31(2):213–9.
   PubMed Web of Science ®Google Scholar
• Ozawa S, Abu-Zeid M, Kawakubo Y, et al. (1990). Monomorphic and polymorphic isozymes of arylamine N-acetyltransferases in hamster liver: purification of the isozymes and genetic basis of N-acetylation polymorphism. Carcinogenesis 11:2137–44.
   PubMed Web of Science ®Google Scholar
• Parkin DP, Vandenplas S, Botha FJH, et al. (1997). Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 155:1717–22.
   PubMed Web of Science ®Google Scholar
• Parmley WW. (1983). Cardiac failure. In Rosen MR, Hoffman BF, eds. Cardiac therapy. Bosten: Kluwer Academic Publishers, 177–80.
   Google Scholar
• Paykel ES, West PS, Rowan PR, Parker RR. (1982). Influence of acetylator phenotype on antidepressant effects of phenelzine. Br J Psychiatry 141:243–8.
   PubMed Web of Science ®Google Scholar
• Payton MA, Sim E. (1998). Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants. Biochem Pharmacol 55(3):361–6.
   PubMed Web of Science ®Google Scholar
• Peng DR, Birgersson C, von Bahr C, Rane A. (1984). Polymorphic acetylation of 7-amino-clonazepam in human liver cytosol. Pediatr Pharmacol (New York) 4(3):155–9.
   PubMedGoogle Scholar
• Peppercorn MA, Goldman P. (1972). The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 181(3):555–62.
   PubMed Web of Science ®Google Scholar
• Perera FP, Tang D, Brandt-Rauf P, et al. (2006). Lack of associations among cancer and albumin adducts, ras p21 oncoprotein levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in a nested case-control study of lung cancer within the physicians’ health study. Cancer Epidemiol Biomarkers Prev 15:1417–9.
   PubMed Web of Science ®Google Scholar
• Perry HH, Tan EM, Carmody S, Sakamoto A. (1970). Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med 76:114–25.
   PubMed Web of Science ®Google Scholar
• Perry HM. (1973). Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med 54:58–72.
   PubMed Web of Science ®Google Scholar
• Philip PA, Fitzgerald DL, Cartwright RA, et al. (1988). Polymorphic N-acetylation capacity in lung cancer. Carcinogenesis 9:491–3.
   PubMed Web of Science ®Google Scholar
• Philip PA, Roger HJ, Harper PG. (1987a). Acetylation and oxidation phenotypes in malignant lymphoma. Cancer Chemother Pharmacol 20:235–8.
   PubMed Web of Science ®Google Scholar
• Philip PA, Rogers HJ, Millis RR, et al. (1987b). Acetylator status and its relationship to breast cancer and other diseases of the breast. Eur J Cancer Clin Oncol 11:1701–06.
   Google Scholar
• Pieters FA, Zuidema J. (1987). The absolute oral bioavailability of dapsone in dogs and humans. Int J Clin Pharmacol Ther Toxicol 25:396–400.
   PubMed Web of Science ®Google Scholar
• Platzer R, Küpfer A, Bircher J, Preisig R. (1978). Polymorphic acetylation and aminopyrine demethylation in Gilbert’s syndrome. Eur J Clin Investig 8:219–23.
   PubMed Web of Science ®Google Scholar
• Price-Evans DA. (1992). N-Acetyltransferase. In Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 95–178.
   Google Scholar
• Price-Evans DA. (1993). Genetic factors in drug therapy. Clinical and molecular pharmacogenetics. Cambridge: Cambridge Univerity Press.
   Google Scholar
• Probst MR, Blum M, Fasshauer I, et al. (1992). The role of human acetylation polymorphism in the metabolic activation of the food carcinogen 2-amino-3-methylimidazo-[4,5-f]quinolone (IQ). Carcinogenesis 13:1713–17.
   PubMed Web of Science ®Google Scholar
• Pullar T, Hunter JA, Capell HA. (1985). Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis 44;831–7.
   PubMed Web of Science ®Google Scholar
• Quyyumi AA, Wagstaff D, Evans TR. (1983). Acute hemodynamic effects of endralazine: a new vasodilator for chronic refractory congestive heart failure. Am J Cardiol 51(8):1353–7.
   PubMed Web of Science ®Google Scholar
• Ramsay LE, Silas JH, Ollerenshaw JD, et al. (1984). Should the acetylator phenotype be determined when prescribing hydralazine for hypertension? Eur J Clin Pharmacol 26:39–42.
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Mick R, Berezin F, et al. (1993). Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res 53(10 Suppl):2304–8.
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Mick R, Berezin F, et al. (1991). Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 50:573–9.
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Mick R, Janisch L, et al. (1996). Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics 6(1):91–101.
   Google Scholar
• Ratain MJ, Proper K, Costanza M, et al. (1990). Population pharmacodynamic study of amonafide: CALGB 8862. Proc Am Assoc Cancer Res 31:181.
   Google Scholar
• Ratain MJ, Rosner G, Allen SL, et al. (1995). Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol 13(3):741–7.
   PubMed Web of Science ®Google Scholar
• Reece PA, Cozamanis I, Zacest R. (1980). Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clin Pharmacol Ther 28:769–78.
   PubMed Web of Science ®Google Scholar
• Reece PA, Cozamanis I, Zacest R. (1982). Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine. Eur J Clin Pharmacol 23(6):523–7.
   PubMed Web of Science ®Google Scholar
• Reidenberg MM, Levy M, Drayer DE, et al. (1980). Acetylator status in idiopathic systemic lupus erythematosus. Arthritis Rheum 23:569–73.
   PubMed Web of Science ®Google Scholar
• Reidenberg MM, Martin JH. (1974). The acetylator phenotype of patients with systemic lupus erythematosus. Drug Metab Dispos 2:71–3.
   PubMed Web of Science ®Google Scholar
• Reynell PC. (1961). Prophylactic procaine amide in myocardial infarction. Br Heart J 23:421–4.
   PubMedGoogle Scholar
• Rieder MJ, Shear NH, Kanee A, et al. (1991). Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 49(1):13–7.
   PubMed Web of Science ®Google Scholar
• Robinson DS, Cooper TB, Jindal SP, et al. (1985). Metabolism and pharmacokinetics of phenelzine: lack of evidence for acetylation pathway in humans. J Clin Psychopharmacol 5:333–7.
   PubMed Web of Science ®Google Scholar
• Roden DM, Reele SB, Higgins SB, et al. (1980). Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol 46(3):463–8.
   PubMed Web of Science ®Google Scholar
• Roots I, Drakoulis N, Brockmoller J, et al. (1989). Hydroxylation and acetylator phenotypes as genetic risk factors in certain malignancies. In Kato R, Estabrook RW, Cayen MN, eds. Xenobiotica metabolism and disposition. London: Taylor and Francis. 499–506.
   Google Scholar
• Sadrieh N, Davis CD, Snyderwine EG. (1996). N-acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland. Cancer Res 56(12):2683–7.
   PubMed Web of Science ®Google Scholar
• Saez R, Craig JB, Kuhn JG, et al. (1989). Phase I clinical investigation of amonafide. J Clin Oncol 7(9):1351–8.
   PubMed Web of Science ®Google Scholar
• Sardas S, Cok I, Sardas OS, et al. (1990). Polymorphic N-acetylation capacity in breast cancer patients. Int J Cancer 46(6):1138-9.
   Google Scholar
• Schröder H, Campbell DE. (1972). Absorption, metabolism and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 13(4):539–51.
   PubMed Web of Science ®Google Scholar
• Schröder H, Evans DAP. (1972). Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut 13:278–84.
   PubMed Web of Science ®Google Scholar
• Schulte PA. (1988). The role of genetic factors in bladder cancer. Cancer Detect Prev 11:379–88.
   PubMedGoogle Scholar
• Siegmund W, Fengler JD, Franke G, et al. (1991). N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert’s syndrome. Br J Clin Pharmacol 32:467–72.
   PubMed Web of Science ®Google Scholar
• Seree EJ, Pisano PJ, Placidi M, et al. (1993). Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol 7:69–75.
   PubMed Web of Science ®Google Scholar
• Shah RR, Smith RL. (2012). Phenocopy and phenoconversion: do they complicate association studies? Pharmacogenomics 13(9):981–4.
   PubMed Web of Science ®Google Scholar
• Shah RR, Smith RL. (2015). Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol 79(2):222–40.
   PubMed Web of Science ®Google Scholar
• Shambaugh GH, Jr. (1966). History of sulphonamides. Arch Otolaryn 83:27–8.
   Google Scholar
• Shenfield GM, McCann VJ, Tjokresetio R. (1982). Acetylator status and diabetic neuropathy. Diabetologia 22:441–4.
   PubMed Web of Science ®Google Scholar
• Shiokawa S, Yasuda M, Nobunaga M. (1992). Genotypes of polymorphic arylamine N-acetyltransferase in systemic lupus erythematosus. Arthritis Rheum 35(11):1397–9.
   Google Scholar
• Sim E, Laurieri N. (2018). Drug metabolism and pharmacogenetics then and now. In Sim E, Laurieri N, eds. Arylamine N-acetyltransferases in health and disease: from pharmacogenetics to drug discovery and diagnostics. Singapore: World Scientific Publishing Co., 3–41.
   Google Scholar
• Siraki AG. (2013). Free radical metabolites in arylamine toxicity. Adv Mol Toxicol 7:39–82.
   Google Scholar
• Sirot EJ, van der Velden JW, Rentsch K, et al. (2006). Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf 29:735–68.
   PubMed Web of Science ®Google Scholar
• Skog KI, Johansson MAE, Jägerstad MI. (1998). Carcinogenic heterocyclic amines in model systems and cooked foods. A review on formation, occurrence and intake. Food Chem Toxicol 36:879–96.
   PubMed Web of Science ®Google Scholar
• Smelt VA, Upton A, Adjaye J, et al. (2000). Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos. Hum Mol Genet 9;1101–07.
   PubMed Web of Science ®Google Scholar
• Sone T, Zukowski K, Land SJ, et al. (1991). Acetylation of 2-aminofluorene derivatives by dog hepatic microsomes. Carcinogenesis 12;1887–91.
   PubMed Web of Science ®Google Scholar
• Stanley LA, Sim E. (2018). Arylamine N-acetyltransferases in normal and abnormal embryonic development. In Sim E. Laurieri N, eds. Arylamine N-acetyltransferases in health and disease: from pharmacogenetics to drug discovery and diagnostics. Singapore: World Scientific Publishing Co., 109–32.
   Google Scholar
• Steele MA, Burk RF, DesPrez RM. (1991). Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 99:465–71.
   PubMed Web of Science ®Google Scholar
• Strandberg I, Boman G, Hassler L, Sjöqvist F. (1976). Acetylator phenotype in patients with hydralazine-induced lupus syndrome. Acta Med Scand 200:367–371.
   PubMedGoogle Scholar
• Sunahara S, Urano M, Ogawa M. (1961). Genetical and geographical studies on isoniazid inactivation. Science 134:1530–1.
   PubMed Web of Science ®Google Scholar
• Tačić A, Nikolić V, Nikolić L, Savić I. (2017). Antimicrobial sulfonamide drugs. Adv Technol 6(1):58–71.
   Google Scholar
• Tan EM, Rubin RL. (1984). Autoallergic reactions induced by procainamide. J Allergy Clin Immunol 74:631–4.
   PubMed Web of Science ®Google Scholar
• Temesvári M, Kóbori L, Paulik J, et al. (2012). Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. J Pharmacol Exp Ther 341:294–305.
   PubMed Web of Science ®Google Scholar
• Tiemersma EW, Kampman E, Bueno de Mesquita HB, et al. (2002). Meat consumption, cigarette smoking, and genetic susceptibility in the etiology of colorectal cancer: results from a Dutch prospective study. Cancer Causes Control 13;383–93.
   PubMed Web of Science ®Google Scholar
• Tiitinen H. (1969). Isoniazid and ethionamide serum levels and inactivation in Finnish subjects. Scand J Respir Dis 50:110–24.
   PubMedGoogle Scholar
• Tilstone WJ, Margot T, Johnstone EC. (1979). Acetylation of phenelzine. Psychopharmacology 60:261–5.
   PubMed Web of Science ®Google Scholar
• Tóth K, Csukly G, Sirok D, et al. (2016). Optimization of clonazepam therapy adjusted to patient’s CYP3A status and NAT2 genotype. Int J Neuropsychopharmacol 19(12):pyw083.
   PubMed Web of Science ®Google Scholar
• Tóth K, Csukly G, Sirok D, et al. (2017). Potential role of patients' CYP3A-status in clozapine pharmacokinetics. Int J Neuropsychopharmacol 20(7):529–37.
   PubMed Web of Science ®Google Scholar
• Trepanier LA, Cribb AE, Spielberg SP, Ray K. (1998). Deficiency of cytosolic arylamine N-acetylation in the domestic cat and wild felids caused by the presence of a single NAT1-like gene. Pharmacogenetics 8:169–79.
   PubMedGoogle Scholar
• Trepanier LA, Ray K, Winand NJ, et al. (1997). Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochem Pharmacol 54:73–80.
   PubMed Web of Science ®Google Scholar
• Tsirka T, Konstantopoulou M, Sabbagh A, et al. (2018). Comparative analysis of xenobiotic metabolising N-acetyltransferases from ten non-human primates as in vitro models of human homologues. Scientific Reports 8, Article number: 9759.
   Google Scholar
• Turesky RJ, Le Marchand L. (2011). Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines. Chem Res Toxicol 24(8):1169–214.
   PubMed Web of Science ®Google Scholar
• Tyrer P, Gardner M, Lambourn J, Whitford M. (1980). Clinical and pharmacokinetic factors affecting response to phenelzine. Br J Psych 136:359–65.
   PubMed Web of Science ®Google Scholar
• van Hees PA, van Elferen L, van Rossum JM, Tongeren JH. (1978). Hemolysis during salicylazosulfapyridine therapy. Am J Gastroenterol 70:501–05.
   PubMed Web of Science ®Google Scholar
• Vandenburg MJ, Wright P, Holmes J, et al. (1982). The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype. Br J Clin Pharmacol 13:747–51.
   PubMed Web of Science ®Google Scholar
• Vatsis KP, Weber WW. (1997). Acetyltransferases. In Sipes IG, McQueen CA, Gandolfi AJ, eds. Comprehensive toxicology. New York: Pergamon, Vol 3, 385–99.
   Google Scholar
• Venkatesan K. (1989). Clinical pharmacokinetic considerations in the treatment of patients with leprosy. Clin Pharmacokinet 16:365–86.
   PubMed Web of Science ®Google Scholar
• Vlahov V, Bacracheva N, Tontcheva D, et al. (1996). Genetic factors and risk of agranulocytosis from metamizol. Pharmacogenet Genomics 6(1):67–72.
   Web of Science ®Google Scholar
• Votoček E, Leminger O. (1932). Sur la β-phenyléthylhydrazine. Collect Czech Chem Commun 4:271–81; C.A. 26: 5294 (1932).
   Google Scholar
• Waller AR, Chasseaud LF, Taylor T, et al. (1979). Plasma concentrations and pharmacokinetics of dihydralazine after single oral doses to human subjects. Biopharm Drug Dispos 1(2):59–64.
   PubMed Web of Science ®Google Scholar
• Weber WW, Hein DW. (1965). N-Acetylation pharmacogenetics. Pharmacol Rev 37(1):25–79.
   Google Scholar
• Weber WW. (1973). Acetylation of drugs. In Fishman WH, ed. Metabolic conjugations and metabolic hydrolysis. London: Academic Press, Vol. 3, 249–96.
   Google Scholar
• Weber WW. (1987). The acetylator genes and drug response. Oxford: Oxford University Press.
   Google Scholar
• Weber WW. (1997). Pharmacogenetics. Oxford: Oxford University Press.
   Google Scholar
• Webster DJ, Flook D, Jenkins J, et al. (1989). Drug acetylation in breast cancer. Br J Cancer 60(2):236–7.
   Google Scholar
• Weiner M, Burman W, Vernon A, et al. (2003). Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 167:1341–7.
   PubMed Web of Science ®Google Scholar
• Wild D, Feser W, Michel S, et al. (1995). Metabolic activation of heterocyclic aromatic amines catalyzed by human arylamine N-acetyltransferase isozymes (NAT1 and NAT2) expressed in Salmonella typhimurium. Carcinogenesis 16(3):643–8.
   PubMed Web of Science ®Google Scholar
• Wohlleb JC, Hunter CF, Blass B, et al. (1990). Aromatic amine acetyltransferase as a marker for colorectal cancer, environmental and demographic associations. Int J Cancer 46:22–30.
   PubMed Web of Science ®Google Scholar
• Wolkenstein P, Carriere V, Charue D, et al. (1995). A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 5:255–8.
   PubMedGoogle Scholar
• Wolkenstein P, Loriot M-A, Aractingi S, et al. (2000). Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS. Pharmacogenetics 10:821–8.
   PubMedGoogle Scholar
• Woosley RL, Drayer DE, Reidenberg MM, et al. (1978). Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 298:1157–9.
   PubMed Web of Science ®Google Scholar
• Wozel G. (1989). The story of sulfones in tropical medicine and dermatology. Int J Dermatol 28(1):17–21.
   PubMed Web of Science ®Google Scholar
• Wu H, Dombrovsky L, Tempel W, et al. (2007). Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. J Biol Chem 282:30189–197.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Suou T, Hirayam C. (1986). Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 6:295–8.
   PubMed Web of Science ®Google Scholar
• Ylitalo P, Ruosteenoja R, Leskinen O, Metsä-Ketelä T. (1983). Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide. Eur J Clin Pharmacol 25:791–5.
   PubMed Web of Science ®Google Scholar
• Zacest R, Koch-Weser J. (1972). Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin Pharmacol Ther 13:420–425.
   PubMed Web of Science ®Google Scholar
• Zanrosso CW, Emerenciano M, de Aguiar Gonçalves BA, et al. (2010). N-acetyltransferase 2 polymorphisms and susceptibility to infant leukemia with maternal exposure to dipyrone during pregnancy. Cancer Epidemiol Biomarkers Prev 19(12):3037–43.
   PubMed Web of Science ®Google Scholar
• Zhang K, Gao L, Wu Y, et al. (2015). NAT1 polymorphisms and cancer risk: a systematic review and meta-analysis. Int J Clin Exp Med 8(6):9177–91.
   PubMed Web of Science ®Google Scholar
• Zhong X, Hui C, Xiao-Ling W, et al. (2010). NAT2 polymorphism and gastric cancer susceptibility: a meta-analysis. Arch Med Res 41:275–80.
   PubMed Web of Science ®Google Scholar
• Zhu YI, Stiller MJ. (2001). Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 45:420–34.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Zhang J, Jiang W, et al. (2015). Risks on N-acetyltransferase 2 and bladder cancer: a meta-analysis. Onco Targets Ther 8:3715–20.
   PubMed Web of Science ®Google Scholar
• Zielińska E, Niewiarowski W, Bodalski J, et al. (1997). Arylamine N-acetyltransferase (NAT2) gene mutations in children with allergic diseases. Clin Pharmacol Ther 62(6):635–42.
   PubMed Web of Science ®Google Scholar
• Zienolddiny S, Campa D, Lind H, et al. (2008). A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis 29:1164–69.
   PubMed Web of Science ®Google Scholar